EU-IPFF committed to promoting research in Pulmonary Fibrosis

Clinical Trial to Evaluate the Safety and Efficacy of DWN12088 in Patients With IPF

Study Purpose

This is a randomized, double-blinded, placebo-controlled multicenter study to evaluate the safety and efficacy of DWN12088 in patients with Idiopathic Pulmonary Fibrosis.

Recruitment Criteria

Accepts Healthy Volunteers Healthy volunteers are participants who do not have a disease or condition, or related conditions or symptoms	No
Study Type An interventional clinical study is where participants are assigned to receive one or more interventions (or no intervention) so that researchers can evaluate the effects of the interventions on biomedical or health-related outcomes. An observational clinical study is where participants identified as belonging to study groups are assessed for biomedical or health outcomes. Searching Both is inclusive of interventional and observational studies.	Interventional
Eligible Ages	40 Years and Over
Gender	All

More Inclusion & Exclusion Criteria

Inclusion Criteria:

- Male or female patients aged ≥40 years based on the date of the written informed consent form.

- Diagnosis of IPF as defined by American Thoracic Society/European Respiratory Society/Japanese Respiratory Society/Latin American Thoracic Association guidelines.

- In a stable condition and suitable for study participation based on the results of medical history, physical examination, vital signs, 12-lead ECG, and laboratory evaluation.

- Patients receiving local standard-of-care for IPF, defined as either pirfenidone or nintedanib, at a stable dose for at least 3 months prior to screening, or neither pirfenidone nor nintedanib.

If the patients were on pirfenidone or nintedanib previously and have been off for at least 3 months prior to screening, they will be considered as not on any treatment for IPF.

- Meeting all of the following criteria during the screening period: - FVC ≥40% predicted of normal.

- DLCO corrected for Hgb ≥25% and ≤80% predicted of normal.

- forced expiratory volume in the first second/FVC (FEV1/FVC) ratio ≥0.7 based on pre-bronchodilator value.

Exclusion Criteria:

- Acute IPF exacerbation within 6 months prior to screening and/or during the screening period.

- Patients who are unwilling to refrain from smoking within 3 months prior to screening and until the end of the study.

- Female patients who are pregnant or nursing.

- Abnormal ECG findings.

- Use of any investigational drugs for IPF within 4 weeks prior to screening

Trial Details

Trial ID: This trial id was obtained from ClinicalTrials.gov, a service of the U.S. National Institutes of Health, providing information on publicly and privately supported clinical studies of human participants with locations in all 50 States and in 196 countries.	NCT05389215
Phase Phase 1: Studies that emphasize safety and how the drug is metabolized and excreted in humans. Phase 2: Studies that gather preliminary data on effectiveness (whether the drug works in people who have a certain disease or condition) and additional safety data. Phase 3: Studies that gather more information about safety and effectiveness by studying different populations and different dosages and by using the drug in combination with other drugs. Phase 4: Studies occurring after FDA has approved a drug for marketing, efficacy, or optimal use.	Phase 2
Lead Sponsor The sponsor is the organization or person who oversees the clinical study and is responsible for analyzing the study data.	Daewoong Pharmaceutical Co. LTD.
Principal Investigator The person who is responsible for the scientific and technical direction of the entire clinical study.	Song
Principal Investigator Affiliation	AIDS Malignancy Consortium
Agency Class Category of organization(s) involved as sponsor (and collaborator) supporting the trial.	Industry
Overall Status	Recruiting
Countries	Korea, Republic of, United States
Conditions The disease, disorder, syndrome, illness, or injury that is being studied.	Idiopathic Pulmonary Fibrosis

Additional Details

This is randomized, double-blinded, placebo-controlled multicenter study to evaluate the safety and efficacy of DWN12088 in patients with Idiopathic Pulmonary Fibrosis.

Arms & Interventions

Arms

Experimental: DWN12088 Xmg Tablet (BID)

PRS inhibitor

Placebo Comparator: Placebo 0mg Tablet (BID)

Placebo

Interventions

Drug: - DWN12088

DWN12088 Xmg Tablet (BID)

Drug: - Placebo

Placebo 0mg Tablet (BID)

Contact a Trial Team

If you are interested in learning more about this trial, find the trial site nearest to your location and contact the site coordinator via email or phone. We also strongly recommend that you consult with your healthcare provider about the trials that may interest you and refer to our terms of service below.

Pulmonary Associates, PA, Mesa, Arizona

Status

Recruiting

Address

Pulmonary Associates, PA

Mesa, Arizona, 85206-1346

Site Contact

Daewoong Pharmaceutical, Co.,Ltd

Clinical Trial Finder